Dislipidemia aterogénica ...|373
7.
Keene D, Shun-‐Shin MJ, Francis DP (2014) Effect on cardiovascular risk of HDL
targetet drug treatments niacin, fibrates, and CETP inhibitors: meta-‐ analysis of
randomised controlled trials including 117411 patients. BMJ 349, g3743.
8.
Libby P. (2014) Triglycerides on the rise: should we swap seats on the seesaw? Eur
Heart J 29, 1-‐3.
9.
Millán I, Botet IP, Brea A, Diaz A, González P, HernándezA, Mantilla T, Pinto X,
SimóR(2014) Consenso de expertos sobre propuestas para la mejora del manejo
de la dislipidemia aterogénica Rev Esp. Cardiol 67, 36-‐44.
10.
Nordestgaard B, Varbo A. (2014) Triglycérides and cardiovascular disesase Lancet
384, 626-‐635.
11.
Rader D, Hovingh GK (2014) HDL and cardiovascular disease. Lancet 384, 618-‐
625.
12.
Rizzo M, Berneis K (2005) Lipidid triad or atherogenic lipoprotein phe-‐notype: a
role in cardiovascular prevention. J AtherosclerThromb 12, 237-‐239.
13.
Sack F, Carey V, Fruchart JC (2010( Combination LipidTherapy in type 2 diabetes.
N Engl J Med 363, 692-‐694.
14.
Sirimarco G, Labreuche J, Bruckert E, Goldstein L, Fox K, Rothwell P, Amarenco P
(2014) Atherogenic Dislipidemia and residual cardiovascular risk in statins-‐
treated patients. Stroke 45, 1429-‐1436.
15.
Tenenbaum A, Fisman E (2012) Fibrates are an essential part of modern anti –
dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk
reduction. Cardiovasc Diabetol 11, 125-‐135.
16.
Tenembaum A, Fisman E, Motro M, Adler Y (2006) Atherogenic dyslipidemia in
metabolic syndrome and type 2 diabetes: Therapeutic options beyond statins.
Cardiovasc Diabetol 5, 20-‐28.
17.
Zimmet P, Alberti K, Serrano Rios M (2005) Una nueva definición mundial del
síndrome metabólico propuesto por la IDF: fundamento y resultados Rev Esp
Cardiol 58, 1371-‐1376.
